Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06222125 | A Study of HB0025 Injection in Patients With Advanced Renal Cancer | unknown | Phase 2 | 100 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03532737 | Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer | unknown | Phase 2 | 50 | Kuwait Cancer Control CenterOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05186012 | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 51 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04914390 | A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer(NeoATCT) | unknown | Phase 2 | 32 | Sichuan Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT05464173 | Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib(CINDERELLA) | unknown | Phase 1 / Phase 2 | 44 | Biyun Wang, MDOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06217003 | Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06202014 | Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT03146650 | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer | unknown | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03708822 | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT05084677 | Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer | unknown | Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06210438 | SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases | unknown | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06211023 | A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | unknown | Phase 2 / Phase 3 | 520 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Jan 18, 2024 | clinicaltrials |
| NCT05065021 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | unknown | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05435313 | Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | unknown | Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05629429 | Olaparib Maintenance Therapy in Metastatic Breast Cancer | unknown | Phase 2 | 300 | National Taiwan University HospitalOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04398524 | A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | unknown | Phase 2 | 65 | ISA PharmaceuticalsINDUSTRY | 9 | Jan 16, 2024 | clinicaltrials |
| NCT05962450 | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | unknown | Phase 2 | 84 | Beijing YouAn HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04617457 | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas(HOLIPANC) | unknown | Phase 2 | 150 | University of CologneOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06201507 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | unknown | Phase 2 | 44 | Beijing Children's HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05296278 | Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC | unknown | Phase 2 | 70 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05296603 | Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 83 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06198465 | Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma | unknown | Phase 2 | 24 | Xijing HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06197438 | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | unknown | Phase 2 | 36 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 46 | Chinese PLA General HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05590221 | Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma | unknown | Phase 2 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06195683 | Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.(NSCLC) | unknown | Phase 2 | 23 | Zhejiang Cancer HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04197492 | Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | unknown | Phase 2 | 22 | Huashan HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05626569 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01541709 | Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI | unknown | Phase 2 | 23 | Asan Medical CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04589754 | Adriamycin and Ifosfamide Combined With Sintilimab | unknown | Phase 2 | 176 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT05859477 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer(NIVOFGFR2) | unknown | Phase 2 | 23 | Kidney Cancer Research BureauOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma(Glioblastoma) | unknown | Phase 1 / Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT06186609 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | unknown | Phase 2 | 68 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT03807102 | Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer(TVATLC01) | unknown | Phase 1 / Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04715217 | Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04937972 | SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma(FLYFLY) | unknown | Phase 2 | 71 | Hunan Province Tumor HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05611879 | Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | unknown | Phase 2 | 30 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT02098954 | Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers | unknown | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03646968 | Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study(SAVE) | unknown | Phase 2 | 43 | Yongchang ZhangOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06104553 | A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma | unknown | Phase 1 / Phase 2 | 132 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 24, 2024source: clinicaltrials